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Expression of G protein-coupled receptor kinase 2 (GRK2) and the related protein GRK5 
plays a vital role in the regulation of cardiac activity by inhibiting G protein-coupled receptor 
(GPCR) signaling in the heart. GPCRs such as the 1-adrenergic receptor, which control the 
contractility of the heart, are dramatically down-regulated during heart failure, a consequence of 
overexpression of GRK2 and GRK5. Previous studies have indicated that the overexpression of 
GRK2 and GRK5 can lead to heart failure in mouse models. The goal of my first project was to 
identify small molecule inhibitors that selectively targeted GRK2 over other GRKs. In this study, 
we conducted screens at the Center for Chemical Genomics which identified a small molecule, 
paroxetine, which displaces an RNA aptamer bound to the active site of GRK2. Follow up 
analysis with kinase activity assays demonstrated selective inhibition of the protein against other 
GRK subclasses. This study was followed by a parallel project with the goal of identifying 
selective inhibitors of GRK5. In this project with GRK5, we started off by screening using a 
thermostabilization assay, which is more applicable to the screening of proteins that do not have 
a competitive binding molecule similar to GRK2’s aptamer. Using similar techniques, a small 
molecule, amlexanox, was identified as a relatively selective and potent inhibitor of GRK5. 
Introduction 
G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are the largest transmembrane receptor family in 
humans and a popular target in pharmacology, with around 50% of all medications acting on 
them
1
. As transmembrane proteins, they act to induce intracellular responses from extracellular 
signals through ligand binding. Also known as “serpentine receptors”, these proteins consist of 
seven transmembrane domains and each receptor is associated with G proteins, which act as 
intermediaries between the stimulation of the receptor and the secondary messenger signaling 
cascade, leading to a variety of responses.  
These receptors are responsible for the regulation of a number of universal physiological 
responses, which include visual and olfactory sensing, immune system and inflammation 
regulation, autonomic nervous system transmission, and cell density sensing. Consequently, 
misregulation of GPCR signaling has been connected to multiple conditions, which include 





G protein-coupled receptor kinases 
One of the mechanisms by which these signaling cascades are regulated is through G 
protein-coupled receptor kinases (GRKs). In the event of stimulation of GPCRs, GRKs function 
to inhibit the signaling cascade by phosphorylating the serine or threonine residues on the 
intracellular loops and/or C-terminus of the active receptor, which in turn increases the binding 
of arrestins on the intracellular side of the protein
3
. Once bound, arrestin inhibits signaling from 
the receptor in multiple ways. Steric hindrance against the coupling interaction between the 
receptor and the G protein allows for continuous ligand binding on the extacellular side of the 
receptor, but does not allow for the stimulation of the associated intracellular G protein. rrestins 
also recruit other proteins through a scaffolding mechanism that inhibits the receptor through 
activation of the extracellular-signal regulated kinase (ERK) pathway or through the 
sequestration of the receptor via endocytosis into the cell. The endocytosis of the receptor allows 
for variable regulation, based on the type of desensitization required. For long-term exposure to a 
hormone, the receptors are only sequestered and dephosphorylated, allowing them to be re-
integrated back onto the membrane, resensitizing the cell. In different circumstances, the 
receptor may be degraded via lysosomes and never return back to the cell surface
4
. All of these 
mechanisms effectively desensitize the receptor from extracellular ligand binding by uncoupling 





Figure 1. GRK regulation of GPCRs 
A GPCR on the membrane is activated via a hormone (in this case epinephrine) or some other agonist and stimulates 
nucleotide exchange on the G protein alpha subunit (Gα) which activates the G protein. Once activated, the Gα and 
Gβγ subunits dissociate from each other and activate downstream signaling cascades. GRK is then able to associate 
with and phosphorylate the active receptor. The phosphorylated carboxyl terminal binds to an arrestin, which 
initiates the inactivation of the receptor. The receptor is later able to be reactivated once arrestin dissociates, and the 
GPCR again couples with the heterotrimeric G protein. 
 
There are seven different GRKs (GRK1-GRK7) in humans, which are categorized into 
three different sub-families of GRKs based on structural homology and functional similarities
6
. 
The GRK1 sub-family, which is also known as the rhodopsin kinase family, consists of GRK1 
and GRK7. These are mostly expressed in the retina and are mostly involved in dampening 
reactions to light in the retina. The GRK2 sub-family, which is also known as the -adrenergic 
receptor kinase family, consists of GRK2 and GRK3. These are expressed in many different 
organs throughout the body such as in the heart, lungs, brain, and placenta, and function in a 
wide range of regulatory roles. GRK2 and GRK3 both require binding to membrane-associated 
Gβγ for activity in living cells
7
. The final sub-family (GRK4) consists of GRK4, GRK5 and 
GRK6. These members are widely expressed, and are found in a variety of organs
8, 9, 10, 11
. GRK5 
is considered the most widely expressed member of this subfamily. Unlike the GRK2 sub-




GRKs and Cardiac Regulation 
-adrenergic receptors are GPCRs that respond to epinephrine to control the contractility 
of the heart to regulate the force at which the heart beats. In human myocardial cells, the 1 and 
the 2-adrenergic receptors are the main regulators of adrenergic effects through coupling with a 
specific Gα protein
13
. Increased stimulus via these catecholamines, such as epinephrine leads to 
tension and hyperactivity, as the sympathetic nervous system is forced to meet the energy needs 
associated with increased activity and physical exertion. Chronic stimulation of the 1-adrenergic 
receptor in particular has been associated with negative effects on overall myocardial health
14
. 
Similarly, it has been shown that there is a strong correlation between decreased density and 




The expression of G protein-coupled receptor kinases 2, 3 and 5 (GRK2, GRK3 and 
GRK5, respectively) plays a vital role in the regulation of this cardiac activity, with GRK2 and 
GRK5 being the primary GRKs expressed in the myocardium
9, 12, 20
. In situations where the -
adrenergic receptors (ARs) are upregulated, the return to homeostasis via downregulation of 
the receptors is mediated by these GRKs. It is believed that the downregulation of -AR 
signaling mediated by GRKs is a mechanism to protect against catecholamine cytotoxicity. 
Pathological downregulation of the receptor occurs in instances where there is chronic 
catecholamine release, such as during heart failure. The subsequent decrease in cardiac output 
from GRK signaling also leads to continued stimulation of the sympathetic nervous system, 
ultimately resulting in a feedback loop which leads to the dramatic down regulation of the 
receptor
21
. The over-expression of GRKs has been found to play a key role in conditions such as 
heart failure in numerous experimental models
18-20, 22-31





Figure 2. β-adrenergic receptor regulation by GRK2/5 
The β-adrenergic receptor, which controls the contractility of the heart via stimulation of adenylyl cyclase and 
protein kinase A, is acted upon by catecholamines (CA) such as epinephrine. Binding of epinephrine stimulates the 
β-adrenergic receptor, causing an increase in contractility. Prolonged CA signaling leads to increased production of 
GRK2/5, which phosphorylate the receptor and triggers its desensitization. The up-regulation of GRK2/5 has the 
possibility of leading to heart failure by severely down-regulating this receptor, compromising cardiac function, and 
making the heart incapable of pumping blood throughout the body. 
 
G protein-coupled receptor kinase 2 





, and myocardial ischemia
22
. An increase in GRK2 expression has also been shown 
to be strongly correlated to the onset of heart failure, suggesting it as a potential therapeutic 
target
23, 28, 34
. GRK2, when active, phosphorylates the 1-adrenergic receptor (1-AR) and, 
through the previously discussed mechanisms, decreases the sensitivity to agonist stimulation 
thereby counteracting the induction of hypertension, thus decreasing the contractility of the 
heartbeat. When GRK2 is overexpressed, the 1-AR is severely downregulated, sometimes 
resulting in heart failure. In vivo studies have shown that inhibition of GRK2 has prevented heart 
failure in mouse models, making it a prime therapeutic target. The identification of small 
molecule inhibitors of GRK2 would be a step towards a new treatment for heart failure. Rather 
than aiming at the receptor, which has been targeted by other beta-blocking drugs, we would be 
targeting a different part of the pathway that underlies many aspects of heart failure. Based on 
this premise, the overall goal of the first project is to find small molecules that selectively inhibit 
GRK2, thus preventing the effects of its over-expression.  
 
G protein-coupled receptor kinase 5 
 Similar to GRK2, GRK5 plays a significant role in regulating cardiac contractility by 
inhibiting the 2-adrenergic receptor (2-AR). Overexpression of GRK5 has been shown to play 
a role in heart failure in mouse models
5
. GRK5’s nuclear localization in myocardial cells and 
more gradual changes in expression during heart failure make it unique in terms of its overall 
contribution to disease, and it has been suggested that GRK5 directly affects hypertrophic gene 
transcription
35
. The phosphorylation of the 2-AR by GRK5 desensitizes the receptor in a 
manner similar to GRK2’s desensitization of the 1-AR. GRK5 overexpression as an 
overcompensating response to the stimulation of the 2-AR analogously leads to the decrease in 
contractility demonstrated with GRK2
 36-38
. Consequently, the inhibition of GRK5 expression in 
these instances has demonstrated to be protective against heart failure
39
. Whereas GRK5 
inhibition correlates strongly with cardiac protection, no bioavailable inhibitors have been 
discovered for GRK5. The goal of the second project was to screen for selective small molecule 
inhibitors of GRK5 using procedures similar to those used in the screening of GRK2 inhibitors. 
 The discovery of a specific inhibitor of GRK5 serves multiple purposes. A bioavailable 
inhibitor would be a novel therapeutic approach towards protecting against heart failure. As of 
yet, no safe and marketable medications targeting this particular protein have been reported. 
With the knowledge of its therapeutic potential, a bioavailable inhibitor could open up new 
avenues of cardiovascular treatment. The discovery of a new binding molecule to the protein 
GRK5 could also aid in the elucidation of the protein’s structure. As of yet, no structure has been 
found for GRK5, making a more stable tertiary conformation desirable for further studies with 
the protein. Obtaining clues about the structure of the protein could potentially serve as a starting 
point for subsequent experiments and aid in the design of a new and more specific inhibitor. 
 
Previously Studied GRK Inhibitors 
 Other GRK inhibitors have been described, but none have ever been selected for 
clinical trials due to a lack of selectivity and/or oral bioavailability. These known inhibitors 
include sangivamycin, balanol, the Takeda compounds 101 and 103A, and the RNA aptamer 
C13. These previously studied GRK inhibitors are used in the project as controls for our own 
screening efforts. 
Sangivamycin, an adenosine analog (Figure 3A) that mimics the substrate ATP, which is 
used for phosphorylation of activated GPCRs
40
. This allows sangivamycin to bind in the active 
site of GRK2 and inhibit kinase activity. Balanol is a natural product that acts as a nonselective 
AGC kinase inhibitor (Figure 3B). It has also been shown to selectively inhibit certain GRK 
subfamilies by binding to the kinase site. Balanol induces a more closed, but not completely 
closed, active site on the protein, forming a unique and inactive conformation
41, 42
. Takeda 
Pharmaceuticals, Inc. reported in a patent the development of potent and selective inhibitors of 
the GRK2 subfamily that were proven to bind in the active site of the enzyme
42, 43
. These 
compounds, 101 and 103A, never made it to clinical trials, presumably due to their low 
bioavailability (Figures 3C and 3D). 
 












Figure 3. Known Inhibitors of GRK2 
(A) Sangivamycin, (B) Balanol, (C) Takeda Compound 101, and (D) Takeda Compound 103A. These inhibitors 
were used as controls for various stages of the study. 
 
 In a previous study, an RNA aptamer called C13 was found to selectively inhibit GRK2 
with a Kd= 1.5 nM. The aptamer forms contacts both inside and around the active site
44
 (Figure 
4A). Crystallographic studies done using a truncated form of the aptamer (C13.28) demonstrated 
that the binding of this aptamer to GRK2 induces a novel conformation of the protein, suggesting 
that compounds that competitively displace this aptamer might also induce a unique and stable 
conformation.  
It should be noted that RNA aptamers are not considered viable therapeutics for 
pharmacological study with regards to oral therapy. It has been shown that these polymers have 
many of the properties characteristic of potential intracellular inhibitors such as selective 
interaction, relatively high affinities for protein binding, and inhibition of catalytic activity on the 
target protein
45-47
. The problem lies in their bioavailability, as there is no technology as of yet to 
facilitate their transmembrane delivery into the target cells. It is thus believed that an ideal 
solution for both pharmacological study and medical application would be in the area of small 
molecule inhibitors, which are more bioavailable than their RNA counterparts and able to more 
selectively inhibit certain parts of a protein rather than affecting the entire structure. For the first 
C D 





Figure 4. RNA aptamer C13 interacts with GRK2  
(A) The aptamer C13 was used in this experiment as a competitive and selective inhibitor for GRK2
44
. (B) For flow 
cytometry protein interaction assay (FCPIA) testing, C13.28-FAM, was used in competition with the various 





Flow Cytometry Protein Interaction Assay (FCPIA).  
RNA aptamers have been used to identify other specific small molecule inhibitors in 
aptamer-displacement assays
48
. With the aptamer’s selectivity and high affinity for binding to 
GRK2, the C13 aptamer is much more likely to be out competed for binding to GRK2 only by 
other selective and high affinity compounds
44
. In this assay, we used the C13.28 aptamer, a 
truncated form which has a shorter stem loop structure, to test for competitive binding of small 
molecules to GRK2. 
For our primary screening of compounds, we used a Flow Cytometry Protein Interaction 
Assay (FCPIA), a high-throughput bead-based flow cytometry assay that had previously been 
shown to successfully measure protein-protein interactions with GRK2
50
. GRK2 was 
A B 
biotinylated using an amine-reactive probe (Sigma) and purified over a gel-filtration column. 
The biotinylated protein was attached to streptavidin-coated polystyrene beads (Spherotech) as 
shown in Figure 4B, forming a covalent-like interaction to ensure a high signal. This was done 
by incubating beads in 18 M protein for at least 30 min. Extraneous unbound protein was taken 
out of solution so as not to cause background interference in the assay. The beads were spun 
down and resuspended in flow buffer (20 mM HEPES pH 7.0, 50 mM NaCl, 5 mM MgCl2, 1 
mM CHAPS, 0.2% lubrol, and 2 mM DTT) at 12 rcf for 60 seconds. The supernatant was 
removed, beads were resuspended in 1 mL of flow buffer, and the process was repeated three 
times. The final concentration of GRK2 used in these assays was 10 nM for each sample tested. 
The bound GRK2 was then incubated with the test compounds. The compounds were 
dissolved in pure DMSO and stored on stock plates at room temperature at a concentration of 1 
mM. Compounds were placed with buffer on 384-well plates (Corning) at a final concentration 
of 10 µM with 1% DMSO using a Beckman Biomek FX robot (Beckman Coulter). GRK2 and 
the test compounds were then left to incubate for thirty minutes on the plate. 
The final step involved the binding of the RNA aptamer to the protein. A truncated and 
fluorescein-labeled form of the aptamer (C13.28-FAM, Figure 4B) was used for the assay to test 
for competitive binding against the test compounds. The labeled aptamer had been proven to be 
indefinitely stable when stored at -80˚C and stable for up to 5 days when kept on ice, dispelling 
any concerns that degradation could occur in the assay. To initiate interaction between the GRK2 
and the aptamer, C13.28-FAM was plated with a final concentration of 2 nM and allowed to 
incubate for 1 hr.  
Once the mixture had had time to reach equilibrium, the displacement of the C13.28-
FAM and binding of the compounds to GRK2 was measured using an Accuri C6 Flow 
Cytometer and analyzed using Accuri HyperCyt software. Each well was gated, and the amount 
of fluorescence was measured for each well. The fluorescent level indicated the amount of 
binding activity between the protein and the compound. With competitive binding, we would 
expect that the protein would displace C13.28-FAM, thus decreasing the fluorescence of the 
protein on the beads. Therefore, the less fluorescent signal read by the flow cytometer, the 
greater the amount of binding implied between the compound and the protein.  
Each plate had positive and negative controls in order to gauge how much of an effect 
each compound had on signaling. The positive control consisted of blank beads, which gave off 
no fluorescent signal, representing a protein bound to a compound which fully competed against 
aptamer for binding. The negative control consisted of beads that were directly attached to 
C13.28-FAM-bound GRK2 in the presence of a DMSO control. This sample represented a 
compound that did not bind at all to the protein, failing to compete with the RNA aptamer. Based 
on these readings, we were able to determine the relative binding activity of each compound onto 
GRK2. 
FCPIA, although extremely effective in its ability to test for competitive binding, can 
only be used to test for GRK2 inhibitors. This test was only effective against this particular 
member of the GRK family due to the fact that the RNA aptamer used for competitive analysis 
was specific for GRK2. Other RNA aptamers with specific binding for the other various GRK 
proteins have not been developed, and thus are not available for usage in competition assays. 
 
Aptamer-Based FCPIA Control Assay 
Because this assay was dependent on the change in fluorescence upon C13.28-FAM 
binding to the protein, these results were then tested against a second control screen. This 
consisted of testing the selected compound hits against plates that contained streptavidin beads 
labeled only with biotinylated aptamer (b-C13.28-FAM) and no protein. Any compounds that 
interfered with the assay by binding to the aptamer and not to the protein or interfered directly 
with fluorescence readings were dismissed, and those hits that gave negative readings against the 
confirmation aptamer assay were followed up on. 
 
FCPIA Dose Response Assay 
In order to assess the strength of the interaction between the binding compounds and the 
protein (GRK2), a dose response was performed to test the binding activity of the compound at 
various concentrations. In these assays, the compound was diluted down the plate in a two-fold 
dilution series and incubated with a common concentration of GRK2 and C13.28-FAM. The 
concentrations used for dose response ranged from 200 μM to 50 μM. All preparations regarding 
the protein GRK2 and the aptamer did not change from the single-point protocol described above 
for the general screen.  
The binding resulting from the various concentrations of inhibitor can be charted in a 
dose response curve which can be used to quantify the potency of the compound against the 
protein (Figure 5). This quantification is measured by determining the IC50 value, or the half-
maximal inhibition concentration. The IC50 value is the concentration of the compound which 
decreases the activity of the protein to half of its native biochemical activity. This is based upon 
the controls in each plate that represent full activity (or no binding) and completely inhibited 
activity (100% binding). In FCPIA, the IC50 would represent half-maximal binding of the 
aptamer C13.28-FAM.  
Control screens similar to those of the original, single-point FCPIA assays were also used 
here for determining compound-aptamer interaction. b-C13.28-FAM was attached to streptavidin 
beads and used in place of protein when incubated with the series of compound concentrations. 
This was used to determine the strength of the interaction between the compounds and the 
aptamer and compare it to the interaction between the compound and the protein.  
 
 
Figure 5. A typical normalized dose response curve obtained using FCPIA. This curve depicts the complete 
competition of unlabeled C13.28 aptamer against labeled C13.28-FAM for binding to GRK2. 
 
Thermofluor Assay 
This stability of a protein can be gauged by measuring its melting temperature (Tm), 
which is the temperature at which a protein population denatures. A protein-compound complex 
which forms a stabilizing interaction requires more heat to denature the protein, whereas a 
compound which destabilizes the protein will cause the protein to denature at a lower 
temperature. These interactions, as measured through shifts in melting temperature from pure 
protein to protein-compound interaction, strongly correlate with the level and nature of the 
binding reactions that take place between the selected small molecules and the protein. The 
thermofluor assay is a test that determines the melting point of GRK2 while interacting with a 
compound by analyzing the changes in the state of the structure over a wide temperature range.  
1-anilinonaphthalene-8-sulfonic acid (ANS) is a fluorescent compound that fluoresces at 
a wavelength of 380 nm
51
 (Figure 6A). The fluorescence of ANS is quenched in aqueous 
solution, but increases in nonpolar environments. Using ANS (Sigma), we can observe the 
thermal denaturation of GRKs over our chosen range of temperatures. Once ANS interacts with 
the hydrophobic residues found at the interior of the protein structure, the fluorescence reading 
increases. The greater the fluorescence reading, the more exposed hydrophobic regions are 
interacting with ANS. 
 
 
Figure 6.  
(A) 1-anilinonaphthalene-8-sulfonic acid (ANS) only fluoresces in non-polar environments. In the thermofluor 
assay, this is used to measure the denaturation of the protein, as fluorescence can be used to measure the amount of 
interaction ANS has with the hydrophobic interior of the protein
51
. (B) As a control, ATP bound to GRK5 shows a 
significant increase in Tm with a ΔTm of 15.5˚C. The graph for thermofluor takes on a characteristic sigmoidal curve 
with three distinct regions. These areas represent (1) a baseline of completely natured and stable protein-compound 
complex, (2) the increase in signal associated with the denaturation of the protein, and (3) the plateau indicating a 







For this assay, compounds were set on a 384 well plate either by using the Beckman 
Biomek FX robot (Beckman Coulter) or by hand with a pipette at a volume of 0.2 μL. All of the 
compounds used were in solution with DMSO at varying concentrations based upon the 
compound. With a final volume of 5 μL, the concentration of the compound from the stock 
solution was diluted by ~25x, making the DMSO concentration negligible for each experiment. 
The compounds were plated with negative controls of DMSO alone. 
The protein and ANS were placed into a single stock solution with 20 mM HEPES pH 
7.0, 5 mM MgCl2, 1 mM CHAPS, and 2 mM DTT, with a final concentration between 0.075 
mg/mL-0.2 mg/mL for the GRKs and 100 μM for the ANS. 5 μL of the stock solution was added 
to each of the wells and spun down in a plate centrifuge for 1 min at 1000 rpm. After spinning 
the plate to ensure that the solution is at the bottom of the well, 2 μL of silicon oil (Aldrich) was 
added to the top of the well to ensure minimal evaporation during the course of the experiment 
and the plate was spun again. The protein-compound-ANS mixture was then incubated for 15-45 
min, allowing the compound and protein to interact. 
The plate was read using a ThermoFluor machine (Johnson & Johnson) over a 
temperature range appropriate for the protein being tested. GRK2 has a melting temperature of 
36.6˚C, which is higher than that of the other GRKs. In contrast, GRK5 only has a melting 
temperature of 25.9˚C, while GRK1 has a melting temperature of ~22.3˚C. The ranges of 
temperatures tested in the thermofluor assay were changed accordingly. For GRK2, the 
temperature range generally used was 25˚C-70˚C, while GRK1 and GRK5 are tested at 15˚C-
60˚C.  
Over these ranges of temperatures, the graph that results from each sample takes on a 
characteristic curve that can be broken down into three sections (Figure 6B). The first section is 
the baseline which indicates a stable protein-compound equilibrium. At this point, the protein has 
not yet begun to denature and is still in its native conformation. The second part of the graph 
shows the steady increase in fluorescence signal which indicates the process of denaturation of 
the protein. As the protein continues to be denatured, the ANS has more access to the interior 
hydrophobic residues, resulting in this sudden increase in signal. The final part of the graph is the 
plateau indicating the completely denatured state of the protein. The graph as a whole is read as a 
sigmoidal curve, with the point of inflection used as the melting temperature of the protein 
(Figure 6B).  
Two different settings for the reading of the plate were used for various experiments. 
Continuous Ramp was used for the GRK2 experiments, where the machine gradually increased 
the temperature by 1˚C over a period of 1 min and then took a reading for each set degree. The 
problem that came from this was that the signal would increase as the protein denatured, reach a 
peak, and then decline at the highest temperatures. Therefore, the third part of the graph would 
show a negative slope instead of forming a plateau. This decline in signal would change how the 
program interpreted the data, as it would not be able to fit a sigmoidal curve to calculate the 
melting temperature of the protein. In some cases where this happens, the decline in signal is due 
to the protein aggregating as they become denatured, thereby decreasing the total amount of 
surface area that interacts with the ANS in solution. In our case, the problem was most likely that 
there were temperature-dependent interactions that happened between the ANS and the 
compound, thereby allowing the ANS to give off a fluorescent signal when in contact with the 
compound rather than with the hydrophobic residues on the interior of the protein. 
After this was noticed, the Up/Down Ramp setting was used for the remaining 
experiments. The Up/Down Ramp, instead of simply increasing the temperature over time, 
returns back to the lowest temperature set in the range before proceeding to the next step, in 
order to take fluorescent readings at a constant temperature. In some cases, this allows for the re-
folding of the protein before each increase in temperature, thus preventing the aggregation that 
can be observed in the Continuous Ramp setting, and also preventing some of the interactions 
between the compound and ANS which influenced ANS’s signal. While the Continuous Ramp 
gave us accurate and replicable results, the Up/Down Ramp allows us to more accurately fit a 
curve onto the data and obtain a consistent melting temperature for the protein. 
The stabilization of the protein by the compound was quantified by calculating the 
difference in melting temperature between the protein-compound complex and the native protein. 
A positive change in melting temperature (ΔTm) would indicate a stabilizing interaction, while a 
small or nonexistant change in temperature suggests little to no interaction between the 
compound and the protein. Negative ΔTm values are interpreted as destabilizing interactions, 




GRKs are kinases, meaning that they phosphorylate proteins using ATP as a substrate. 
The phosphorylation assay uses four primary ingredients: the kinase (GRK2 or GRK5), a protein 
substrate (bovine rhodopsin [bROS] or tubulin), magnesium, and ATP. The magnesium in this 
situation acts as a cofactor for the reaction, as it binds to the enzyme with ATP. The ATP 
provides the phosphate group that will be transferred on the substrate. The use of radioactive 
phosphorus allows us to track the movement of the phosphate group from the ATP to the 
substrate (Figure 7A). A large amount of radioactive material in the protein after the assay 
indicates a greater amount of catalytic activity. By comparing the levels of catalytic activity, we 
will be able to tell the amount of inhibition mediated by small molecules as they interact with the 
kinase as well as their potency. 
Two different protein substrates were used for these reactions. Tubulin is a soluble 
protein that is easily phosphorylated by GRKs, although with less efficiency than GPCRs. The 
other substrate, bovine rhodopsin (bROS), is a readily available light-activated GPCR that serves 
as a substrate for all GRKs. Rhodopsin is expressed in the retina and enables low-light vision. 
Rhodopsin contains a chromophore, 11-cis-retinal, that undergoes an irreversible isomerization 
upon absorption of a photon of light. Therefore, this protein must be processed in the dark, and 
can only be exposed to light during the reaction (after ATP has been added). Despite their 
differences, each of these substrates is able to accurately measure the activity of the compound-
bound protein, and both are used to add variability to the different experiments performed.  
In these projects, phosphorylation assays were used to measure the potency of the 
compounds. Dose response curves were fitted for each of the compounds, allowing us to find 
IC50 values, quantifying the strength of the inhibitor in relation to catalytic activity. A series of 
dilutions were made for each of the compounds and plated in duplicate. Stock solutions for the 
GRK and the substrate were also made at this time using 20 mM HEPES pH 7.0, 2 mM MgCl2. 
For the kinase, the stock concentration was 200 nM, with a final reaction concentration of 50 
nM. The substrate was at a concentration of 2 μM, for a final reaction concentration of 500 nM. 
The compounds were then incubated with both the kinase and the substrate for ~30 min to allow 
for binding of the inhibitor.  
An ATP stock solution was made up at 20 μM with an approximately 20 μCi of 
radioactive ATP added for every 150 μL of stock made. This ATP stock solution was added and 
allowed to react for a set amount of time before the reaction was quenched with SDS loading 
dye. Various tests were done to optimize the reaction time that allowed the kinase to act on the 
protein while still demonstrating the amount of inhibition provided by the compound. We wanted 
to keep the reaction in the “first-order”, or linear, part of the overall reaction, which is where the 
velocity of the reaction is essentially constant. This optimization would result in a better fitting 
curve for the dose response and thereby allow for more accurate calculation of the IC50 values for 
each sample. 
Each of the samples was run on a 12% SDS-PAGE gel at 225V for 45 min. The resulting 
gel was dried with a marker of 1:1000 diluted ATP stock. The marker would later be used to 
calculate the amount of radioactivity in each sample. The gels were then developed on a Storage 
Phosphor Screen (GE Healthcare), which would later be scanned using a Typhoon 9410 scanner 
(Amersham) for quantification of the radioactivity in each of the samples. Data was analyzed 
using ImageQuantTL software (GE Healthcare). From the quantified radioactivity levels for each 
sample, dose response curves could be formed to determine the IC50 values in relation to 

















Figure 7. Phosphorylation assay is used to measure potency of each compound 
(A) In phosphorylation assays, the activity of the kinase is measured using radioactive 
32
P-ATP, whose terminal 
radioactive phosphate is incorporated into the rhodopsin or tubulin substrate. (B) The calculated dose response curve 
is generated as a measure of activity based upon different concentrations of inhibitor against the enzyme and permits 




The search for a specific inhibitor of GRK2 started from screening small molecule 
compound libraries, and grew more selective with each elimination. This was done with the 




range of different assays, potency, selectivity, and competitive binding were analyzed for a 
variety of compounds. We later progressed to a parallel project involving GRK5, using many 
similar techniques to screen for selective small molecule inhibitors, with our primary screening 
process being the major difference between the two. While GRK2 was screened using a 
competition based assay, GRK5 was screened based on protein-compound stabilizing 
interactions. 
Flow Cytometry Assay Development 
One of the main assays used in screening for GRK2 inhibitors was FCPIA. Before testing 
began on compounds, the FCPIA was tested using some of the previously studied binding agents 
and inhibitors of GRK2. These included ATP, unlabeled aptamer (C13.28), sangivamycin
40
, and 
the Takeda compound 103A (Figure 8).  
It was found that the most potent competitors of C13.28-FAM binding were unlabeled 
C13.28 (pIC50 = 9.3) and 103A (pIC50 = 8.6), which were able to completely reduce the 
fluorescence signal to the positive control levels. Lower affinity compounds ATP (Km=28 μM) 
and sangivamycin (IC50 =70 μM) were only able to decrease fluorescence by 40-70% over the 
concentrations evaluated. Although these two were able to decrease affinity between the aptamer 
and GRK2, they did not fully compete, indicating allosteric modulation of aptamer binding. 
Their competition with C13.28-FAM resulted in pIC50 values of 4.3 and 5.0 respectively. 
 
Figure 8. Tests of known inhibitors of GRK2 in the aptamer displacement assay  
The inhibitors sangivamycin and Takeda compound 103A were used in preliminary testing, along with ATP and 




Primary Screen of GRK2 against the Center for Chemical Genomics (CCG) Compound Library 
We began the search for inhibitors by conducting FCPIAs on GRK2 against a collection 
of ~40,000 compounds. These compounds were part of a larger 100,000 compound library 
purchased from ChemDiv and housed at the CCG at the University of Michigan’s Life Sciences 
Institute. Out of the ~40,000 compounds that were tested in this preliminary screening, we 
identified 6017 compounds that blocked the binding of the RNA aptamer inhibitor C13.28-FAM 
to the active site of GRK2 with a standard deviation > 3 by plate (Figure 9).  
After conducting the counterscreen, we found that a large number of the compounds 
interfered directly with the fluorescence signaling by directly interacting with the C13.28-FAM. 
For this round of selection, new parameters were placed in order to narrow down a more potent 
and specific list of compounds for a second round of screening. Using a cutoff of standard 
deviations greater than 3 and greater than 20% activity based on the controls of each plate, we 
selected 1811 compound hits for continued testing. These compounds were then put through a 
FCPIA confirmation screen, in which they were plated and tested in triplicate at a concentration 
of 100 μM. 412 of the remaining compounds were found to retain greater than 20% activity 
based on three independent experiments.  
In a collaboration with the University of New Mexico’s Center for Molecular Discovery, 
a separate set of 1,200 compounds from the university’s Prestwick Chemical Library was also 
screened in the same manner as the 40,000 ChemDiv Library. Similar parameters were put into 




Figure 9. Primary screening of GRK2 using FCPIA 
In a single-point FCPIA, competitive binding is measured in relation to the positive and negative controls (10 µM 
C13.28 and DMSO respectively). In the primary screen, the definition of a “hit” involved looking at the standard 





FCPIA Dose Response Titrations of GRK2 
Dose response curves were performed in order to test the potency of the 412 selected 
compounds from the CCG on GRK2. Each of the selected compounds was serially diluted in 
duplicate down the plate with a highest concentration of 50 μM and a lowest concentration of 
0.78 μM and levels of the fluorescence were measured at each concentration. From the FCPIA 
data collected from these plates, we were able to build dose response curves that told us how 
well each compound bound relative to the other compounds. This was measured and quantified 
using a half-maximal inhibition concentration value (IC50) which is the concentration required 
for 50% inhibition based on plate controls. Within this set of 412 compounds, the cutoff was set 
at a pIC50 (-logIC50 value) of 4 or greater. This narrowed the field of samples down to 237 
compounds. 
Dose response curves were also generated a different set of 20 compounds from a screen 
of the ChemDiv 100,000 compound library (Figure 10). With a highest concentration of 100 μM 
and a lowest concentration of 0.78 μM, these sets were done in duplicate. The control aptamer 
screen was also performed on this set of compounds in dose titration format, in order to clearly 
assess the results gained from the GRK2 assay. Some of the problems that arose from this 
particular set of compounds involved solubility issues. For this particular experiment, the 
compounds had to be soluble in 200 μM stock solutions. In order to prevent complete 
precipitation, a few of the compounds had to be solubilized with as much as 33% DMSO. This 
posed a problem with regards to the DMSO affecting the state of the protein, and this caveat had 
to be taken into account when assessing the results.  
From this set of 20 compounds, we found that there were several compounds with low 
IC50 values that were to be further examined. From those that seemed to have lower 
concentration IC50 values, the control screen against the aptamer demonstrated that these hits 
were compounds that interfered directly with the aptamer or quenched the fluorescence signal, 
and did not interact with the protein. In later experiments where three of the 20 compounds were 
re-examined in dose response with a highest concentration of 100 μM, it was found that their 
IC50 values only came to 50 μM or higher, which is not low enough to be considered for 
pharmacological testing. These compounds were thus determined as not worthy of further 
pursuit, and the project shifted its focus back onto the hits from the 40,000 compound screen. 
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Figure 10. Dose response curves from 20 compounds from a ChemDiv screen 
Subsequent experiments revealed that the hits from this set of compounds also interfered directly with the C13.28 




























GRK2 Thermofluor Screening 
Out of the 40,000 compounds originally screened, we found 237 compounds that were 
capable of displacing the RNA aptamer from the active site of GRK2 in dose dependent manner. 
These compounds were then selected for additional testing with a Thermofluor assay. The 
compounds were each tested in triplicate over a temperature range of 25˚C-70˚C.  
Compounds were selected for advancement if they had a Hill slope between -2 and 2, 
IC50 values ≤30 µM, and median ΔTm values >0.16˚C. From this list of 237 compounds, 37 were 
selected. Out of these, only 32 compounds were purchased due to their market availability.  
 
FCPIA Dose Response Titrations of Selected Compounds Against GRK2 
As a result of the collaboration with the University of New Mexico’s Center for 
Molecular Discovery, two compounds were found in the Prestwick Collection that were able of 
efficiently displacing the RNA aptamer. These compounds (P-851 and P-835) were confirmed 
with dose response titrations using the FCPIA with a highest concentration of 100 µM.  A 
control dose response was also done using the b-C13.28-FAM and the compounds did not 
demonstrate any significant interaction or interference with the aptamer. The controls used for 
this plate were the same as previously used positive and negative controls of no GRK2 and no 
compound interference, as well as a separate set of controls composed of the known GRK2 
inhibitors balanol and Takeda compound 103A. These inhibitors were used in order to compare 
the shape and the magnitude of the responses of the test compounds.  
These dose response curves were performed in triplicate and were used to narrow down 
the field of compounds. Any compounds that consistently demonstrated dose dependent effects 
and were definitively proven to not interfere with the aptamer were selected for additional 
analysis. From this selection, the number went from 34 compounds (2 identified at UNM and 32 
we purchased as described above) to a set of 15, which included the 2 compounds found by the 
University of New Mexico. One of these compounds, P-851, shown in Figure 11, was among the 
strongest compounds identified with a measured pIC50 value of ~4.5 ± 0.2. 
 
 
Figure 11. Paroxetine FCPIA dose response 
FCPIA Dose Response data for compound P-851 (paroxetine) consistently showed a pIC50 value of 4.5 ± 0.2. This 
compound was followed up on with thermofluor testing. 
 
Thermofluor Dose Dependence 
By comparing the changes in Tm at a few concentrations, we can get a relative idea of the 
potency of each compound. Unlike FCPIA, dose response data in thermofluor is not considered 
as reliable due to the fact that changes in Tm based on compound concentration happen in too 
narrow of a concentration range. As a result, the dose response curve for thermofluor is 
sometimes considered too steep to be a reliable source. For our purposes, a few concentrations 
were tested to look at the dose dependence of protein-compound stability.  
The 15 remaining compounds were tested at varying dosages to check for potency in 
thermofluor. The concentrations used were 200 μM, 100 μM, and 50 μM (Figure 12). Within this 
range of concentrations, variation between the Tm values of each compound was generally not 
significant. In thermofluor screening, the values that are considered “significant” are dependent 
on the protein and the substrates being tested. For GRK2, many hits for thermofluor testing have 
ΔTm values <1˚C, with 1˚C considered as a significant shift for this particular assay. In striking 
contrast to the other compounds, P-851 consistently shifted the melting temperature of GRK2 by 
~7.8˚C for each concentration. For comparison, ATP, the native substrate for GRK2, gives a Tm 
shift of 1.5-5.6˚C at these concentrations, with a ΔTm of ~4.9˚C at 200μM ATP-Mg
2+
. This 
suggests that P-851 has high affinity for GRK2.  























































Figure 12. Dose dependent thermofluor  
Thermofluor data measuring dose dependence for the selected 15 compounds at concentrations of 50μM, 100μM 




The dose dependent thermofluor data yielded 6 compounds that were considered worth 
pursuing in additional GRK selectivity experiments. 5 of the compounds increased the stability 
of the structure and gave positive ΔTm values, while 1 compound was categorized as a 
destabilizing molecule, showing a negative ΔTm value. Destabilizing compounds, while not 
generally applicable as inhibitors, can be used to understand interactions between the protein and 
the compound. By understanding these interactions and those of the stabilizing compounds as 
well, we could potentially use these structures as the foundation for drug design research. These 
6 compounds along with ATP were screened at a concentration of 200 μM against GRK1 and 
GRK5, representative members of the other GRK subfamilies (Figure 13). 
4 of the compounds seemed to form more selective interactions, having a more stabilizing 
effect on GRK2 than on the other GRK subtypes. These included Compound 1 (ΔTm = 0.40˚C), 
Compound 23 (ΔTm = 0.99˚C), Compound P-851 (ΔTm =7.8˚C), and Compound P-835 (ΔTm = 
0.73˚C). This was in contrast to the other GRK subtypes, with GRK1 having melting temperature 
shifts of -0.09˚C (Compound 1), -0.66˚C (Compound 23), 0.95˚C (Compound 851), and -0.15˚C 
(Compound P-835), and GRK5 melting temperature shifts with -1.55˚C (Compound 1), -0.37˚C 
(Compound 23), -0.35˚C (Compound P-851), and -0.01˚C (Compound P-835). The single 
destabilizing compound was not found to be selective and was dismissed from further 
investigation.  
From this set of experiments, P-851 continued to stand out as a particularly strong 
inhibitor candidate. From the thermofluor selectivity data, P-851 demonstrated selective 
stabilization of GRK2 in comparison to the other GRK subgroups, with a ΔTm <1˚C for both 
GRK1 and GRK5. P-851 also managed to induce melting temperature shifts which were larger 




















































































































Figure 13. Thermofluor GRK selectivity data of 6 compounds identified in the FCPIA analysis 
The 6 compounds were tested in thermofluor for stabilization data against representative members of all 3 GRK 
subfamilies. 4 out of the 6 chosen compounds were found to be selective for GRK2 against GRK1 and GRK5. 
Compound P-851 stood out in particular, with a ΔTm value of 7.8˚C for GRK2, while having a ΔTm <1˚C for both of 




Compound P-851 (Paroxetine) Structure Activity Relationships 
 P-851 (henceforth called paroxetine) consistently demonstrated in FCPIA a pIC50 value 
of 4.5 ± 0.2 (Figure 11) and a ΔTm of 7.8˚C in Thermofluor analysis (Figure 12). With follow-up 
analysis, a crystal structure of the protein-compound complex was obtained by Dr. David Thal in 
the lab, which demonstrated selective binding of paroxetine to GRK2 in a novel conformation
49
.  
Following the elucidation of the structure, we began analyzing structural activity 
relationships (SARs), structural analogs of paroxetine, in an attempt to determine the important 
binding sites of the protein-compound complex. SAR1 is a defluorinated form of paroxetine, 
which was predicted to reduce multiple hydrophobic interactions between the compound and 
GRK2 (Figure 14B), while SAR2 is a desmethylene paroxetine which was predicted to reduce 
favorable van der Waals interactions within the active site of GRK2 (Figure 14C).  
For primary analysis, thermofluor assays were run, comparing the binding and stabilizing 
strength of the SAR compounds against the original hit. Both SAR compounds showed 
decreased thermostabilization as well as decreased inhibition of GRK2 activity in relation to the 
original compound due to fewer intermolecular interactions with the binding site of the protein. 
In thermofluor, in comparison to the 7.8˚C increase in Tm given by the paroxetine-GRK2 
interaction, the SAR interactions were proven to be weaker, as predicted. This was indicated by 
the decrease in ΔTm values for the analogous compounds, with SAR1 found to be a ΔTm of 
4.91˚C, while SAR2 provided a ΔTm value of 5.54˚C (Figure 14D and 14E). Although these are 
still relatively large shifts in melting temperature against GRK2, they are still decreased in 
relation to the original paroxetine structure which had more optimized interactions between the 
compound and the protein. 
Follow-up activity analysis of SAR compounds concluded my direct involvement with 
this particular project, which in turn was followed up with in vivo studies performed by a 
collaborator at Temple University. It was proven that inhibition of overexpressed GRK2 in vivo 
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Figure 14. Paroxetine structure activity relationships 
(A) Paroxetine stood out as a particularly potent compound against GRK2. Structure activity relationships (SARs) 
were studied to determine the nature of the interaction between the compound and GRK2. (B) SAR1 is a 
defluorinated form of paroxetine, while (C) SAR2 is a desmethylene paroxetine. (D and E) As predicted, 
interactions between the SAR compounds and GRK2 were weaker in strength than those of the original paroxetine 
against GRK2. The difference in affinity can be seen by a decrease in melting temperature of the protein-compound 
complex.  
 
GRK5 Thermofluor Screening 
 After the analysis of GRK2 inhibition with P-851, we started work on a parallel and 
related project regarding another member of the GRK family, GRK5. GRK5 represents a 
different subfamily of the GRKs, potentially suggesting unique binding mechanism. GRK5 has 
exhibited regulatory functions in the heart and lungs similar to those of GRK2, suggesting that 
inhibition of GRK5 would result in therapeutic protection against heart failure. As of yet, no 
small molecule inhibitors of this protein have been identified. GRK5 also lacks a known 
structure, and finding a molecule which binds to the active site could potentially facilitate a 
structure determination. 
 The search for a small molecule inhibitor began with the screening of a 16,000 compound 
library from the CCG against GRK5 protein using the thermofluor assay. Preliminary findings 
from previous studies done within the lab have shown that GRK5 has shown promising 
E 
thermostabilization data against both a negative control of DMSO and a positive control of ATP, 
which is known to bind at the active site
49
 (Figure 15A). Although analysis of certain compounds 
for selectivity has been targeted for GRK2 binding, it has been shown that counter-screening 
against GRK5 is capable of identifying specific binding against different GRKs using this assay. 
Thus, it is as an appropriate test for potential inhibitors of the kinase activity. 
 Primary screening on the library began by performing a four-fold multiplex test in 
thermofluor, which involved incubating four compounds per sample of GRK5. Controls for this 
experiment were again DMSO as a negative control and 5 mM ATP as a positive control. 5mM 
ATP with GRK5 gives a ΔTm value of 15.5˚C, with GRK5’s native melting temperature with a 
DMSO control being 25.9˚C. Some concerns were raised regarding the presence of both a 
stabilizing compound and a destabilizing compound being screened in one sample. Although 
interference between the compounds interacting with each other or conflicting with multiple 
interactions on the protein is possible, these concerns were seen as negligible, as the likelihood 
of a strongly stabilizing and a strongly destabilizing compound coming together at random was 
unlikely.  
From the original 16,000 compounds, 60 samples (240 individual compounds) were 
initially identified as potential thermo-modulating compounds. These compounds were selected 
based a criteria of ΔTm > 1.7˚C or ΔTm < -4.9˚C, 2.5 standard deviations away from the native 
melting temperature of the protein. Both stabilizing and destabilizing compounds were selected 
for continued analysis. The destabilizing compounds of GRK5 were chosen for the benefit of 
analyzing inferring interactions between the compound and the protein. 
As an example, one of the hits that we obtained was found to contain a well known 
kinase inhibitor, staurosporine, which gave a multiplex melting temperature shift of 4.4˚C 
(Figure 15B). This was taken as a proof of concept with regards to screening for inhibitors 




Confirmation Thermofluor for GRK5 
These hits were deconvoluted into their individual compounds and tested in a 
confirmation thermofluor assay, with each individual compound tested in quadruplicate. The 
concentration of these compounds was 10 μM, slightly less concentrated than the GRK2 
compounds that were retested based on expected potency of the compounds. Each quadruplicate 
was analyzed as a set, with hits defined as needing significant shifts in 2 or more of the 4 
Figure 15. Thermofluor studies and screening of GRK5 
(A) Previous studies have demonstrated that thermofluor 
studies are able to detect binding of small molecules to 
GRK5. (B) The pan-kinase inhibitor staurosporine in 
multiplex yielded a ΔTm of 4.4˚C, providing proof of concept 




samples. Using parameters of 2.5 standard deviations with ΔTm > 12% or ΔTm < -35% based on 
the controls of DMSO and ATP, we narrowed it down to 20 compounds for follow up in a final 
thermofluor trial (Figure 16). These hits were composed of 17 positive shifts in melting 
temperature and 3 destabilizing hits.  
 
 
Figure 16. GRK5 confirmation hits 
Based on the deconvolution of hits found from the multiplex screen, 20 compounds were confirmed as hits for the 
assay. Out of these 20, 17 of them were stabilizing hits that gave positive ΔTm values, qualifying them as potential 
inhibitors. The other three hits were destabilizing compounds which were investigated for protein-compound 
complex interactions.  
 
Dose dependence testing in thermofluor was the final step in observing the stabilizing 
strength of the compounds within a range of concentrations. Similar to what was done with the 
GRK2 compounds, the 20 compounds were tested in a variety of concentrations ranging from 1 
μM to 120 μM. This once again allowed us to look at relative potency in a broad context without 
determining an exact IC50 value.  
From these final results, 4 compounds were found that were selected as possible 
inhibitors for GRK5.  These results included byssochlamic acid (Figure 17A), amlexanox (Figure 
17B), Box5 (Figure 17C), and CCG-5274-0479 (Figure 17D). 
 
 
    
 
   
 
Figure 17. GRK5 dose dependence 
Dose dependence testing resulted in 4 selected compounds for further analysis in phosphorylation assays. These 
compounds included (A) byssochlamic acid, (B) amlexanox, (C) Box5, and (D) CCG-5274-0479. Out of these 
compounds, amlexanox was chosen as the one compound that merited the most attention in further analysis. 
 
Phosphorylation Screening of GRK5 with Amlexanox 
Ultimately only amlexanox was chosen for further analysis with GRK5 inhibition 
activity. This was based on a variety of factors mostly involving the compatibility of the 




reactive acid anhydride groups was determined to most likely be toxic in a biological system. 
Box5, while not toxic, has a modified peptide structure that makes it more difficult to deliver into 
a cell. This lack of bioavailability eliminated box5 from current avenues of investigation.  
Phosphorylation assays at various concentrations of amlexanox were done to assess 
stabilization and relative potency of the compound. Amlexanox concentrations were tested 
within a range of 125 nM to 1 mM using two-fold dilutions. Through analysis of phosphorylation 
signal over the various concentrations, it was found that amlexanox bound GRK5 with an IC50 of 
10 μM (Figure 18).  
This gave us enough reason to look into the selectivity of the compound against the other 
GRK families. Using the same techniques with amlexanox against GRK1 and GRK2, we found 
that the dose response curves did not converge for these GRKs, indicating that amlexanox does 
not bind or inhibit other GRK subfamilies. This demonstrated that amlexanox forms a unique 
and stabilizing interaction with GRK5 in relation to the other members of the GRK family. It 





















Figure 18. GRK5 phosphorylation with amlexanox 
Amlexanox was tested for inhibition of catalytic activity using phosphorylation assays. Compound potency was 
tested for over a range of concentrations (125 nM-1 mM). GRK5 was shown to have an IC50 value of 10 μM with 
Amlexanox. Selectivity was tested by analyzing inhibition of other members of the GRK family. GRK1 and GRK2, 
representatives of the other subfamilies, were not inhibited by Amlexanox.  
 
Discussion 
GRK2 and GRK5 have both been studied extensively for their regulation of cardiac 
contractility. Kinase inhibitors in general have received a lot of attention by the pharmacology 
community, composing over 25% of all drugs on the market
52
. Most studies aim to find 
inhibitors which directly interact with the active site of the enzyme. This approach is successful 
in finding inhibitors for the kinase activity, but they tend to be nonspecific small molecule 
inhibitors which compete directly with ATP, and hence potentially with many other enzymes that 
bind ATP. 
At the same time, most of the medications which are directed towards preventing or 
treating heart disease are -blockers, compounds aimed at binding and directly inhibiting the β-
adrenergic receptors. While these have proven effective in helping to reduce the rates of 
morbidity and mortality in patients suffering from congestive heart failure
53
, there are certain 
detrimental effects that can result from taking these drugs
54
.  
Using this novel RNA aptamer, C13, our lab was able to target a non-traditional part of 
the sympathetic signaling pathway. Because of the fact that C13 binds and inhibits GRK2 
selectively by inducing a novel inactive conformation of the protein, screening compounds in 
competition with the aptamer implies a much more selective set of hits. This means that in 
conjunction to avoiding the β-adrenergic receptor target, the aptamer ultimately allows us to 
eliminate from the beginning a subset of the non-specific inhibitors which generally associate 
with the more conserved regions of the kinase, the active site associated with ATP binding.  
Through this method of screening, we were able to find one particular compound which 
demonstrates the ability to directly affect the catalytic activity of GRK2 through direct binding 
and stabilization of a novel conformation. Paroxetine has been shown to compete off the aptamer 
with high potency and thermostabilize GRK2 to a greater extent than its native substrate, ATP. 
In a crystallographic study, paroxetine was observed to induce a novel conformation of the 
protein while binding in the ATP binding site
49
. This discovery of a novel conformation which 
drastically stabilizes and inactivates could potentially act as a foundation for future drug design 
with regards to GRK2. Understanding the intermolecular interactions formed by this compound 
will hopefully lead to their optimization in future synthetic studies, thereby providing the 
gateway to a more selective inhibitor of the sympathetic nervous system.  
Paroxetine, as an antidepressant drug, has been on the market since 1992. While it has 
been proven to have these effects on cardiac contractility, there has been no reported correlation 
between paroxetine use and decreased heart failure. In canine models, it has been estimated that 
the blood plasma levels of paroxetine is around 125 nM, which is several factors below the 30 
μM levels estimated for effectiveness against GRK2. However, these levels are not uniform 
throughout the body, with paroxetine concentrating at certain target areas such as the CNS
55
. 
With the discovery of its affinity for GRK2, the effects of paroxetine might now take on a new 
significance. Future directions on this project might include a surveyed investigation of the 
correlation between heart failure rates of patients on paroxetine and those on other -blocker 
medications.  
Exploring the selectivity with regards to binding specificity against other GRK proteins 
also helps us to understand the distinctive structural elements which define the different GRKs. 
As of now, no crystal structure for GRK5 has been generated. This gives the search for an 
interactive compound a slightly different purpose with regards to protein-compound interactions. 
One of the ideas behind looking into molecules which bind GRK5 is the possibility of co-
crystallizing the two and investigating a more stabilized conformation of the structure. By 
elucidating a unique conformation of the protein, we have the potential of generating a model to 
work off of when looking into the native structure of the protein itself and to design new drugs. 
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